NNVC ▲ +5.2% - NanoViricides, Inc. $NNVC - Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides NanoViricides shares rose 5.2% following the company's announcement that it has begun a Phase II clinical trial of its antiviral candidate NV-387 in the Democratic Republic of Congo to treat monkeypox. The initiation of human testing in an actual disease-endemic region represents a significant clinical milestone for the experimental therapy. 23-SEP-2026 08:30 AM ET